Licencing agreement gives Promega exclusive rights to quantitative gene expression assays for the life science research marketplace using technology developed by EraGen
Promega and EraGen Biosciences have signed a licencing agreement giving Promega exclusive rights to quantitative gene expression assays for the life science research marketplace using technology developed by EraGen.
The EraGen technology will enable Promega to offer researchers easier and more accurate methods to measure expressions of nucleic acids.
The Promega/EraGen partnership grants Promega global distribution rights for assays for research.
Promega will develop and manufacture reagent systems. EraGen will provide Promega with patented chemistry and proprietary software.
Launch of the Promega branded product is scheduled for this year.
"This agreement is a result of a strategic relationship that developed through the interactions of our scientists in the Madison biotechnology community." said Bill Linton, president and CEO, Promega.
"It provides us with an opportunity to combine our strengths and deliver a product to researchers that will help them more efficiently determine changes in cellular expression of nucleic acids". The EraGen technology is a patented nucleic acid detection system combining proprietary EraGen chemistry with a novel software package.
The result allows the rapid development of high performance and easy-to-use nucleic acid assays for life science research applications.
"We are very excited about our strategic alliance with a powerful partner like Promega. "Its highly respected reputation and global recognition in the life science research market will drive our technology to wider acceptance.
"Promega should expect rapid market acceptance as validated by our recent Sars detection system. "A market presence by Promega will further enhance EraGen's product development for the clinical diagnostic market," said Irene Hrusovsky, president and CEO of EraGen Biosciences.
